Prevention: Fibrates reduce risk of coronary events

Randomized controlled trials of fibrate therapy have yielded variable results. Although these agonists of peroxisome proliferator receptor alpha (PPAR-α) are known to reduce triglyceride levels and increase HDL-cholesterol concentration, they have not been consistently associated with reduced vascular risk. Furthermore, some studies have raised concerns